1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. North America Hereditary Cancer Testing Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. North America Hereditary Cancer Testing Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. North America Hereditary Cancer Testing Market Regional Analysis
6.2 North America Hereditary Cancer Testing Market Revenue 2016-2027 (US$ Million)
6.3 North America Hereditary Cancer Testing Market Forecast Analysis
7. North America Hereditary Cancer Testing Market Analysis – by Diagnosis Type
7.1 Biopsy
- 7.1.1 Overview
- 7.1.2 Biopsy: North America Hereditary Cancer Testing Market – Revenue and Forecast, 2016-2027 (US$ Million)
7.2 Imaging
- 7.2.1 Overview
- 7.2.2 Imaging: North America Hereditary Cancer Testing Market – Revenue and Forecast, 2016-2027 (US$ Million)
8. North America Hereditary Cancer Testing Market Analysis – by Technology
8.1 Sequencing
- 8.1.1 Overview
- 8.1.2 Sequencing: North America Hereditary Cancer Testing Market – Revenue and Forecast, 2016-2027 (US$ Million)
8.2 PCR
- 8.2.1 Overview
- 8.2.2 PCR: North America Hereditary Cancer Testing Market – Revenue and Forecast, 2016-2027 (US$ Million)
8.3 Microarray
- 8.3.1 Overview
- 8.3.2 Microarray: North America Hereditary Cancer Testing Market – Revenue and Forecast, 2016-2027 (US$ Million)
9. North America Hereditary Cancer Testing Market Analysis – by End User
9.1 Hospital
- 9.1.1 Overview
- 9.1.2 Hospital: North America Hereditary Cancer Testing Market – Revenue and Forecast, 2016-2027 (US$ Million)
9.2 Clinics
- 9.2.1 Overview
- 9.2.2 Clinics: North America Hereditary Cancer Testing Market – Revenue and Forecast, 2016-2027 (US$ Million)
9.3 Diagnostic Centers
- 9.3.1 Overview
- 9.3.2 Diagnostic Centers: North America Hereditary Cancer Testing Market – Revenue and Forecast, 2016-2027 (US$ Million)
10. North America Hereditary Cancer Testing Market – North America Analysis
10.1 Overview
10.2 North America
- 10.2.1 North America Hereditary Cancer Testing Market Breakdown, by Key
Country, 2019 and 2027 (%)
- 10.2.1.1 North America Hereditary Cancer Testing Market – Revenue and
Forecast Analysis – by Country
- 10.2.1.1 US:
North America Hereditary Cancer Testing Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.1.1 US: North America Hereditary Cancer Testing Market Breakdown, by Diagnosis Type
- 10.2.1.1.2 US: North America Hereditary Cancer Testing Market Breakdown, by Technology
- 10.2.1.1.3 US: North America Hereditary Cancer Testing Market Breakdown, by End User
- 10.2.1.2 Canada:
North America Hereditary Cancer Testing Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.2.1 Canada: North America Hereditary Cancer Testing Market Breakdown, by Diagnosis Type
- 10.2.1.2.2 Canada: North America Hereditary Cancer Testing Market Breakdown, by Technology
- 10.2.1.2.3 Canada: North America Hereditary Cancer Testing Market Breakdown, by End User
- 10.2.1.3 Mexico :
North America Hereditary Cancer Testing Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.3.1 Mexico : North America Hereditary Cancer Testing Market Breakdown, by Diagnosis Type
- 10.2.1.3.2 Mexico : North America Hereditary Cancer Testing Market Breakdown, by Technology
- 10.2.1.3.3 Mexico : North America Hereditary Cancer Testing Market Breakdown, by End User
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 Biosero Inc.
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Hologic Inc.
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Koninklijke Philips N.V.
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Quest Diagnostics Incorporated
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Myriad Genetics, Inc.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Cancer Genetics Inc.
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Invitae Corporation
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Myogenes
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Strand Life Sciences Pvt. Ltd.
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Pathway Genomics Corporation
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
13.11 CENTOGENE AG
- 13.11.1 Key Facts
- 13.11.2 Business Description
- 13.11.3 Products and Services
- 13.11.4 Financial Overview
- 13.11.5 SWOT Analysis
- 13.11.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations
Get Free Sample For North America Hereditary Cancer Testing Market
